Future Outlook: Treating Advanced Melanoma

Source: OncLive, February 2019


Axel Hauschild, MD: At the end of our discussion, I want to touch on 2 new components with different modes of action. There is the NKTR component, which is called NKTR-214. There was a trial released at ASCO [American Society of Clinical Oncology Annual Meeting] on this. Merrick, are you familiar with this data?

Merrick I. Ross, MD: No.

Axel Hauschild, MD: How about you, Jason?

read the original full article